Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.43 |
| ▸ | CAPN1 | P07384 | 6/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | GNRHR | P30968 | 3/20 | 0.40 |
| ▸ | NMUR2 | Q9GZQ4 | 3/20 | 0.39 |
| ▸ | NMUR1 | Q9HB89 | 3/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8773027 | 0.92 | APLNR (0.43) | APLNRCAPN1CTSBNMUR2NMUR1 | |
| SCHEMBL29615168 | 0.84 | GNRHR (0.45) | APLNRCAPN1GNRHR | |
| SCHEMBL29383471 | 0.84 | GNRHR (0.45) | APLNRCAPN1GNRHR | |
| SCHEMBL30440639 | 0.79 | OPRM1 (0.47) | APLNRNMUR2NMUR1OPRM1OPRK1 | |
| SCHEMBL30440642 | 0.79 | OPRM1 (0.47) | APLNRNMUR2NMUR1OPRM1OPRK1 | |
| SCHEMBL23470064 | 0.78 | APLNR (0.43) | APLNRCAPN1GNRHRNMUR2NMUR1 | |
| Acetic Acid SCHEMBL30440885 | 0.77 | OPRM1 (0.48) | APLNRNMUR2NMUR1OPRM1OPRK1 | |
| SCHEMBL29391291 | 0.76 | GNRHR (0.47) | GNRHROPRK1MMP1MMP3 | |
| SCHEMBL15342308 | 0.76 | ACE (0.47) | CAPN1CTSBOPRM1 | |
| SCHEMBL24040282 | 0.76 | OPRM1 (0.49) | APLNRCAPN1GNRHRNMUR2NMUR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518890-B2 | Luteinizing hormone-releasing hormone receptor agonist leuprorelin, or antagonist with androgen receptor agonist for prophylaxis, treatment of prostate cancer; dehydroepiandrosterone, testosterone, dihydrotestosterone; non-steroidal androgen receptor agonist; estradiol, estrone, estriol, stilbestrol | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-08-27 | — | — | US | disclosed |
| US-20080138426-A1 | REMEDIES FOR SEX HORMONE DEPENDENT DISEASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080138426-A1 | REMEDIES FOR SEX HORMONE DEPENDENT DISEASE | SHBG, NR5A1, GNRHR | APLNR 447/4885CAPN1 4099/4885CTSB 2445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.